These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 24150416)

  • 1. Engineering synthetic vaccines using cues from natural immunity.
    Irvine DJ; Swartz MA; Szeto GL
    Nat Mater; 2013 Nov; 12(11):978-90. PubMed ID: 24150416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogen-like particles: biomimetic vaccine carriers engineered at the nanoscale.
    Rosenthal JA; Chen L; Baker JL; Putnam D; DeLisa MP
    Curr Opin Biotechnol; 2014 Aug; 28():51-8. PubMed ID: 24832075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic vaccines: the role of adjuvants in immune targeting.
    Jiang ZH; Koganty RR
    Curr Med Chem; 2003 Aug; 10(15):1423-39. PubMed ID: 12871139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The development of synthetic antitumour vaccines from mucin glycopeptide antigens.
    Gaidzik N; Westerlind U; Kunz H
    Chem Soc Rev; 2013 May; 42(10):4421-42. PubMed ID: 23440054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic peptides as vaccines.
    Rothbard JB
    Biotechnology; 1992; 20():451-65. PubMed ID: 1600388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant Newcastle disease virus-vectored vaccines against human and animal infectious diseases.
    Duan Z; Xu H; Ji X; Zhao J
    Future Microbiol; 2015; 10(8):1307-23. PubMed ID: 26234909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity.
    Speiser DE; Romero P
    Semin Immunol; 2010 Jun; 22(3):144-54. PubMed ID: 20413326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In utero DNA immunisation. Immunity over tolerance in fetal life.
    Rizzi M; Gerloni M; Srivastava AS; Wheeler MC; Schuler K; Carrier E; Zanetti M
    Vaccine; 2005 Jul; 23(33):4273-82. PubMed ID: 16005117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasmodium falciparum synthetic LbL microparticle vaccine elicits protective neutralizing antibody and parasite-specific cellular immune responses.
    Powell TJ; Tang J; Derome ME; Mitchell RA; Jacobs A; Deng Y; Palath N; Cardenas E; Boyd JG; Nardin E
    Vaccine; 2013 Apr; 31(15):1898-904. PubMed ID: 23481177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering vaccines and niches for immune modulation.
    Purwada A; Roy K; Singh A
    Acta Biomater; 2014 Apr; 10(4):1728-40. PubMed ID: 24373907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conserved synthetic peptides from the hemagglutinin of influenza viruses induce broad humoral and T-cell responses in a pig model.
    Vergara-Alert J; Argilaguet JM; Busquets N; Ballester M; Martín-Valls GE; Rivas R; López-Soria S; Solanes D; Majó N; Segalés J; Veljkovic V; Rodríguez F; Darji A
    PLoS One; 2012; 7(7):e40524. PubMed ID: 22815759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current issues regarding the application of recombinant lactic acid bacteria to mucosal vaccine carriers.
    Takahashi K; Orito N; Tokunoh N; Inoue N
    Appl Microbiol Biotechnol; 2019 Aug; 103(15):5947-5955. PubMed ID: 31175431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant vaccine delivery systems and encoded vaccines.
    Stover CK
    Curr Opin Immunol; 1994 Aug; 6(4):568-71. PubMed ID: 7946044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. β-Glucan as an immune activator and a carrier in the construction of a synthetic MUC1 vaccine.
    Wang H; Yang B; Wang Y; Liu F; Fernández-Tejada A; Dong S
    Chem Commun (Camb); 2018 Dec; 55(2):253-256. PubMed ID: 30534737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cold-adapted influenza and recombinant adenovirus vaccines induce cross-protective immunity against pH1N1 challenge in mice.
    Soboleski MR; Gabbard JD; Price GE; Misplon JA; Lo CY; Perez DR; Ye J; Tompkins SM; Epstein SL
    PLoS One; 2011; 6(7):e21937. PubMed ID: 21789196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesenchymal stem cells as a novel vaccine platform.
    Tomchuck SL; Norton EB; Garry RF; Bunnell BA; Morris CA; Freytag LC; Clements JD
    Front Cell Infect Microbiol; 2012; 2():140. PubMed ID: 23162801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspective of Peptide Vaccine Composed of Epitope Peptide, CpG-DNA, and Liposome Complex Without Carriers.
    Lee Y; Lee YS; Cho SY; Kwon HJ
    Adv Protein Chem Struct Biol; 2015; 99():75-97. PubMed ID: 26067817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.
    Ryder AB; Nachbagauer R; Buonocore L; Palese P; Krammer F; Rose JK
    J Virol; 2015 Dec; 90(5):2544-50. PubMed ID: 26676789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioconjugate Materials in Vaccines and Immunotherapies.
    Jewell CM; Caruso F
    Bioconjug Chem; 2018 Mar; 29(3):571. PubMed ID: 29558810
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 27.